Percutaneous local ablative therapy (PLAT) is indicated for patients with small HCC (Ͻ5 cm) confined to the liver that is unresectable due to limited liver reserve or compromised liver function. It is usually done through the percutaneous route under ultrasound or computed tomography guidance. The technique is difficult for patients with multiple tumors (more than three) because of the need for repeated puncture. PLAT is contraindicated in patients with
Objective
To review and compare treatment result for percutaneous local ablative therapy (PLAT) with surgical resection in the treatment of small hepatocellular carcinoma (HCC).
Summary Background Data
PLAT is indicated for small unresectable HCC localized to the liver. From the use of ethanol to the latest technology of radiofrequency ablation, ablative techniques have been refined and their role in the management of HCC established. This review aims to give an overview of various ablative methods, including their efficacy, indications, and limitations, and also tries to look into the future of clinical trials in PLAT.
Methods
The authors reviewed recent papers in the English medical literature about the use of local ablative therapy for HCC. Fo-cus was given to the results of treatment in terms of local control, progression-free survival, and overall survival, and to compare treatment results with those of surgery.
Results
PLAT for small HCC (Ͻ5 cm) with thermal ablation (radiofrequency ablation or microwave coagulation) can achieve effective local control of disease and is superior to ethanol injection. Progressive disease in untreated areas is a common reason for failure. Overall progression-free survival is similar to that of surgical resection.
Conclusions
Thermal ablation gives good local control of small HCC, is superior to ethanol, and may be comparable to surgical resection in long-term outcome.
Hepatocellular carcinoma (HCC) is a common disease worldwide. It has been estimated that 315,000 new cases of HCC were diagnosed in 1985, accounting for 4.1% of all human cancer cases in the world. 1 About 70% and 12% of all cases were found in Asia and Africa, respectively. 1 Recent evidence has shown that the incidence and mortality rate of HCC are rising in North America and Europe. 2, 3 The prognosis of HCC is generally poor. Partial hepatectomy remains the best hope for a cure but is suitable for only 9% to 27% of patients. 4, 5 The presence of significant background cirrhosis often precludes liver resection in patients with HCC. Recurrence of tumor within the liver remnant is also common in patients who have undergone "curative" liver resection. Further resection is often not possible for recurrent tumor because of limited liver reserve. In these situations and if the tumor is relatively small (Ͻ5 cm), few in number (three or fewer), and confined to the liver, local ablation of the tumor using minimally invasive techniques is a recognized form of treatment. Local ablative therapy has the advantages of preserving the uninvolved liver parenchyma, has no systemic side effects compared to systemic or intra-arterial chemotherapy, and also avoids the morbidity and mortality of major hepatic surgery. gross ascites, coagulopathy that cannot be corrected, and obstructive jaundice due to the potential risk of bleeding and bile peritonitis. Increased risks of bleeding and peritoneal tumor seeding must be considered when the tumors are situated at or protruding from the liver surface. Tumors hiding under the diaphragm or too close to vital structures (bile ducts, major blood vessels, stomach, gut) would also pose a problem for PLAT.
There are many forms of PLAT (Table 1) , including intralesional injection of agents that have the ability to kill tumor cells (chemicals, radioactive isotopes or chemotherapeutic drugs) or application of an energy source that can produce thermal ablation (such as radiofrequency and microwave), and cryotherapy. PLAT aims at adequate local control of the treated lesion and is used on many occasions as primary treatment for small HCC. It is also sometimes used as a temporizing treatment for selected patients awaiting liver transplant.
PERCUTANEOUS ETHANOL INJECTION THERAPY
Percutaneous ethanol injection therapy (PEIT) was introduced in the 1980s. Intratumoral injection of ethanol causes dehydration and necrosis of cells. This is accompanied by small blood vessels thrombosis that leads to tumor ischemia. PEIT is usually carried out under ultrasound guidance and given until the ethanol is distributed throughout the whole lesion. Sometimes a larger volume is required as some of the ethanol may enter the circulation. PEIT is usually repeated twice a week for up to four to six sessions. Follow-up serum ␣-fetoprotein, ultrasound, and computed tomography are commonly used to monitor the therapeutic response. Additional ethanol injections are repeated for patients with large tumors, incomplete tumor necrosis, or new lesions that are still amenable to local ablation.
Nonrandomized studies have shown PEIT to give a 3-year survival rate of 47% to 77%. 6 -10 However, the rate of posttreatment recurrence within the liver exceeds 50% in 2 years. 8, 9 Two prospective randomized controlled studies have been performed: one trial evaluated PEIT versus no treatment 11 and the other evaluated PEIT plus transarterial chemoembolization against transarterial chemoembolization alone. 12 Both studies showed no impact of PEIT on patient survival, although in these two studies PEIT was used on patients with large HCC. A meta-analysis combining these two randomized studies showed the survival effect at 1 year with PEIT was not significant, 13 but the number of randomized trials is too small to draw a firm conclusion about the survival benefit after PEIT.
PEIT has the advantages of being safe, inexpensive, easy to perform, and repeatable. Side effects are usually minimal, including pain, pyrexia, and a transient rise in liver enzyme. Like all other methods of local ablative therapy, it does not cause significant damage to the surrounding uninvolved hepatic parenchyma. There are also advantages for treating HCC rather than liver metastasis with ethanol. HCC typically occurs against a background of cirrhosis, so that the tumors are "soft" while the surrounding hepatic parenchyma is "hard." This promotes the distribution of ethanol within the tumor, particularly when the HCC is encapsulated. Patients with liver metastases typically have normal (soft) underlying hepatic parenchyma, whereas the metastasis is "hard," a situation that promotes the egress of ethanol from the lesion into the normal liver. 14 In addition, HCC is more hypervascular compared to liver metastasis, so that small vessel thrombosis after ethanol injection would induce more ischemia and necrosis. 14, 15 
PERCUTANEOUS INJECTION OF ACETIC ACID
Acetic acid is another noxious chemical that can be used in PLAT. This was introduced by Ohnishi et al. in 1994. 16 The advantage of acetic acid over ethanol is that acetic acid diffuses into the tumor better. Of the 25 patients with solitary HCC of 3 cm or less, all lesions became smaller after treatment, and two HCC specimens obtained after resection showed complete necrosis as well. The 1-and 2-year survival rates were 100% and 92%, respectively, after treatment. 16 From a subsequent prospective randomized study on 60 patients treated with either 50% acetic acid or PEIT, acetic acid treatment had superior survival (2-year survival 92% vs. 63%) and a lower local recurrence rate (8% vs. 37%). 17
PERCUTANEOUS INJECTION OF YTTRIUM-90 MICROSPHERES
Direct intralesional injection of glass microspheres containing yttrium-90 was reported in 27 patients with HCC 18 More than 90% of the tumors showed a reduction in size, and histologically confirmed complete tumor destruction was found in eight patients. Concern has been raised about the radiation hazards associated with this procedure, including the hazard to the patient when the yttrium-90 microspheres leak outside the liver into the peritoneal cavity. Protection of medical personnel is another concern once surgical intervention is required in case of hemoperitoneum after puncture. 19 
PERCUTANEOUS INJECTION OF HYPERTHERMIC SALINE AND DISTILLED WATER
Cellular injury occurs when the temperature rises to 42°C and above. A temperature up to 60°C can immediately induce death of normal hepatocytes. 20, 21 It is known that tumor cells are more vulnerable to destruction by heat than normal cells because of relative hypoxia and decreased pH levels in the tumor. 22, 23 Therefore, PLAT with hyperthermic saline or distilled water (making use of its additional effect of hypo-osmolarity) can be another option to ablate HCC. This approach may be superior to ethanol because saline or water is more physiologic and can be given in larger volume to treat large tumors. 24 They are also less irritating than ethanol and cause less pain even if there is efflux of the fluid into blood vessels or the peritoneum. The use of percutaneous hot saline injection has been reported to give superior results, 24 especially in treating relatively large tumors. 25 The tumor regression rate was 42% in one study using percutaneous hot saline to treat 29 patients with a median tumor size up to 7 cm. 25 The use of PLAT with hyperthermic distilled water was reported in one study of 21 patients. 26 The side effects of this treatment were minimal, including transient local pain, low-grade fever, and mild elevation of liver transaminase.
PERCUTANEOUS INJECTION OF HYPERTHERMIC CHEMOTHERAPEUTIC AGENTS
Heat can enhance the cytotoxic efficacy of some chemotherapeutic agents. 27 Hence, a combination of heat and chemotherapy can theoretically improve the therapeutic efficacy of conventional chemotherapy. This had been studied in the management of malignancies in clinical settings. 28, 29 Currently, hyperthermic chemotherapy is primarily used as a local ablative therapy, and the temperature is confined to less than 45°C due to the intolerance of tissues to a higher temperature. Intratumoral injection of cisplatin in combination with interstitial laser has been tried. The combined procedure raised the temperature of the center of the tumor to 62.5°C and achieved a 75% tumor regression rate in squamous cell carcinoma. 30 Such an approach can be suitable for local ablation for liver cancer. In one study using animals with liver cancer, intralesional injection of heated carboplatin was given. Extensive necrosis was found in the center of the tumor and to a larger extent than the control group animals that received heated distilled water only. 31 The limitation of this approach is that some chemotherapeutic agents are thermal-sensitive: drugs such as cisplatin are less effective when the temperature is high. 32 Such an approach with hyperthermic chemotherapy remains experimental.
LOCAL INJECTION OF CHEMOTHERAPEUTIC AGENTS
There are few data on the use of local injection of chemotherapeutic agents for HCC. Intralesional injection of cytotoxic drugs can theoretically achieve a high concentration of the drug and may be more effective than systemic administration. However, rapid dispersion of the drug into the circulation defeats the purpose. Recently, a slow-release preparation has been developed that is suitable for intralesional treatment. This preparation of bovine collagen gel contains a stable and homogeneous suspension of cisplatin and epinephrine and was found to be effective in the treatment of advanced solid tumors. 33 From a phase II study on 58 patients with unresectable but localized HCC, response as defined by degree of necrosis was up to 53%. 34 The indications were unresectable tumors fewer than three in number, less than 7 cm in diameter, and less than 200 mL for the total tumor volume. A series from Hong Kong on 17 patients who received such treatment showed that 88% of the lesions showed no evidence of viable tumor on subsequent dynamic study with gadolinium-enhanced T1weighted magnetic resonance imaging. 35 A pharmacokinetic study in parallel to the same clinical study also showed delayed release of cisplatin into the systemic circulation after treatment with the cisplatin/epinephrine gel. 36 
PERCUTANEOUS RADIOFREQUENCY ABLATION
Radiofrequency ablation (RFA) of liver tumors in humans was first described by Rossi et al. in 1993. 37 It is done through a needle electrode (15-18G) with an insulated shaft and a noninsulated distal tip that is inserted into a lesion under image guidance (ultrasound or computed tomography). The patient is made into an electric circuit by placing grounding pads on the thighs or back muscles. The radiofrequency energy emitted from the tip causes ionic agitation and frictional heat, which leads to cell death from coagulation necrosis. Treatment for each tumor by RFA usually lasts 6 to 12 minutes.
Clinical trials with RFA show promising results compared with PEIT. A study from Italy showed that 90% of tumors less than 3 cm achieved complete necrosis after RFA compared to only 80% for PEIT. 38 A similar study from Japan also showed complete tumor necrosis as assessed by Percutaneous Local Ablative Therapy for HCC computed tomography in all 23 patients treated by RFA but in only 94% of patients treated by PEIT. 39 Another study from the United States on 110 patients with HCC who received RFA showed that the local recurrence rate at the treated site was only 3.6% at a median follow-up of 19 months. 40 Compared with PEIT, RFA produced a higher rate of necrosis with fewer treatment sessions. 40 From two prospective randomized studies comparing PEIT and RFA, the number of treatment sessions required for RFA to achieve the same degree of tumor control was less than for PEIT. 41, 42 The study by Lencioni et al. also showed a higher percentage of complete necrosis (91% vs. 85%) and a lower rate of local recurrence (4% vs. 17%) for RFA than PEIT. 41 A more recent prospective randomized study on 102 patients also showed a significant improvement in survival for RFA compared with PEIT. 43 Limitations for RFA remain. When the lesion to be treated is close to heat sinks (structures with a large volume of blood flow, such as the heart and major blood vessels), the heat generated by radiofrequency will be carried away by the blood and make the treatment less effective. For peripheral lesions that abut organs such as the gallbladder, large bowel, or stomach, RFA can damage these organs. Such patients might still be treated laparoscopically so that the organs at risk can be separated physically from the lesion at the time of RFA. 15 Another major limitation relates to the physics of the RFA process. If the electrode tip becomes too hot, tissue charring ensues. This causes increased tissue impedance, which results in decreased energy absorption and a smaller tissue volume. With the conventional monopolar RFA technique, the diameter of coagulation from a single electrode insertion is limited to 1.6 cm. Although large amounts of tissue can be ablated in vitro, the charring and the heat sink problems are difficult to overcome in clinical situations. 15 Different methods of increasing the treatable tumor volume as well as avoiding the problem of charring are being tried. These include injecting saline into the lesion during treatment, 44 cooling the electrode tip, 45 complex electrode geometry, 46 and monitoring the impedance and temperature at the tip while feeding back to adjust the generator output to decrease charring and thus treat a larger volume of tissue. 15 Another potential problem with RFA is tumor seeding; this may also apply to other local ablative methods. From a Spanish study of 32 patients treated with RFA, 12.5% of the patients showed biopsy-proven needle-track seeding 4 to 18 months after RFA. 47 Risk factors included subcapsular location of tumor, poor differentiation of tumor, and high baseline alpha-fetoprotein level. However, the risk is much higher than from other reports. 48 Avoiding the risk factors and performing thermocoagulation of the needle track while removing the needle may reduce the risk of tumor seeding. 49 This is especially important when RFA is used in patients awaiting liver transplantation.
PERCUTANEOUS MICROWAVE COAGULATION THERAPY
Microwave coagulation therapy, another form of thermal ablation for HCC, involves the use of a microwave coagulator that generates and transmits microwave energy to a monopolar-type needle electrode inserted into the liver tumor. The energy causes molecular vibration of dipoles, especially water molecules in tissue, and produces dielectric heat and thermal coagulation around the electrode. 50 Microwave coagulation has been used in liver surgery to control bleeding from ruptured HCC and to decrease bleeding from liver transection planes during liver resection. 51 It is also used to destroy unresectable HCC during laparotomy and laparoscopy. [52] [53] [54] Microwave coagulation therapy can be done through the percutaneous route (PMCT). Microwave electrodes are typically placed through a 14G needle that is positioned under ultrasound or computed tomography guidance. Seki et al. first reported the use of PMCT to treat 18 patients with small HCC in 1994. 55 All treated tumors showed various imaging findings of tissue necrosis, and one of the patients, who underwent hepatectomy after PMCT, had complete necrosis of the tumor after treatment. In a subsequent study from the same group comparing PMCT with PEIT, PMCT gave better local control and longer survival for patients with moderately or poorly differentiated HCC. 56 A study by Dong et al. reported that 84% of the treated lesions showed no evidence of residual disease by imaging and biopsy after PMCT. 50 Limitations for PMCT are similar to those of RFA. While the problem of tumor proximity to heat sinks cannot be solved, and careful patient selection is required to avoid treating these patients with PMCT, larger tumors can be treated in a number of ways by PMCT. Sato et al. reported a method for placing multiple needles for microwave coagulation in an effort to ablate larger tumors in one session. 57 This can allow the use of up to seven electrodes to coagulate an area 50 to 60 mm in diameter. Other series also used multiple electrode insertion and performed multiple treatment sessions for large tumors. 50, 55, 57, 58 Another alternative to treat large tumors is to extend the ablation duration to 300 seconds. 58 Complications of PMCT are similar to those of other PLAT procedures. Caution must be used to prevent skin burns when treating superficial tumors. Dong et al. recommended cooling the skin around the needle with cold saline during treatment. 50 For lesions that abut organs or are inaccessible by the percutaneous route, the laparoscopic 59, 60 or thoracoscopic 61, 62 approach can be used to perform microwave coagulation.
INTERSTITIAL LASER PHOTOCOAGULATION
In interstitial laser photocoagulation (ILP), laser light is emitted from the tip of thin (0.2-0.6 mm in diameter) fibers.
The thermal coagulation effect of ILP results from the heat produced as light energy is absorbed, either directly or after the light is scattered by tissue. The absorption of scattered light results in the greatest penetration and uniformity of energy distribution. 15 The biologic response or extent of necrosis depends on power (in watts), exposure time, wavelength of light, and the absorption characteristics of the tissue, including proximity to major blood vessels. Most studies have used the neodymium:yttrium-aluminum-garnet (Nd:YAG) laser, which emits light with a wavelength of 1,064 nm and provides good penetration and distribution. 15 A single laser fiber may be used to treat tumors up to 1.5 cm in diameter, while multiple fibers may be used to create a larger area of thermal necrosis. 63 In 1989, Steger et al. treated two patients with metastatic liver tumor using ultrasound-guided ILP through the percutaneous route. 64 This treatment has been used predominately in the treatment of unresectable liver metastases, although it has also been used in HCC. [65] [66] [67] The number and size of lesions that can be treated are similar to those currently amenable to treatment by PEIT and RFA. However, lesions as large as 15 cm were treated in one report. 66 ILP is typically performed using local anesthesia and conscious sedation. Laser fibers can be inserted through single or multiple microcatheters or needles as small as 19G for the percutaneous procedure. 64 -69 The procedure can be performed under ultrasound or magnetic resonance guidance. 68, 69 Reported complications of percutaneous ILP include pain, fever, pleural effusion, and subcapsular hematoma. 64 -69 Amin et al. noted less pain related to ILP than PEIT in patients treated for colorectal liver metastases. 65 Most results with percutaneous ILP have been reported in terms of change in tumor size or apparent necrosis based on imaging findings. Early results suggest greater efficacy in smaller lesions. 65, 67 
PERCUTANEOUS CRYOABLATION
Cryotherapy destroys tumor in a non-tissue-specific way. It causes cell death by a variety of physical and chemical mechanisms depending on the rate of cooling, absolute depth of the hypothermia, rate of thawing, number of freeze-thaw cycles used, and the delayed effects of postthaw ischemia. Irrespective of the cooling rate, extensive tissue injury occurs at temperatures below Ϫ20°C. Temperatures below Ϫ40°C are reliably lethal for most tumor cells. Repeated freeze-thaw cycles move the margin of reliable cell kill outward. In addition to the acute physiochemical changes and structural changes in the cell and its environment, the lethal effects of cryoablation are potentiated by the disruption of vascular structures, causing delayed hypoxia and necrosis. 70 Cryotherapy in hepatic surgery has emerged as a promising method for treating HCC, colorectal, and neuroendocrine liver metastases during laparotomy. Complications of cryotherapy include generalized hypothermia, hemorrhage, bile fistula and collections, and cryo-shock. Percutaneous cryotherapy is performed under computed tomography or ultrasound guidance. This approach is still limited by the large diameter of current cryoprobes and location of tumors within the liver. 71, 72 
DISCUSSION
Effective local ablation for small HCC can be potentially curative, as shown by the use of surgical resection, the most effective form of local ablation. Recently, various methods of ablation using nonsurgical methods have been developed, with different degrees of success reported. A good local ablative method should be locally effective to the cancer, nontoxic to nontumorous liver, and easy and safe to administer. The endpoint of local ablation is complete tumor necrosis with a margin of tissue. Of the methods of ablation, PEIT, PMCT, and RFA are commonly performed and are effective as well. For tumors less than 5 cm, the percentages of complete necrosis for treated lesions are over 90% with thermal ablation (PMCT or RFA). 38, 73 However, the percentage of complete necrosis is lower for PEIT. 38 A prospective randomized study has shown that RFA is superior to PEIT in terms of local recurrence rate. 43 The number of sessions required for thermal ablation is also less than that of PEIT. 41, 42 Therefore, thermal ablation has become popular and is the standard treatment in many centers. However, for lesions that are close to the main portal vein or intestine, thermal ablation may not be feasible, and PEIT is preferred. The efficacy between the two thermal ablative methods (PMCT and RFA) seems to be similar, and so far no prospective study has compared the two modalities. The efficacy of local ablation is also dependent on the size of the treated lesion. Tumors larger than 5 cm have a lower percentage of complete necrosis and a higher rate of recurrence. Independent risk factors for recurrence after thermal ablation are hepatitis C infection, multifocal tumor, and a high pretreatment ␣-fetoprotein level. 73 Other innovative local ablation methods such as yttrium-90, interstitial laser therapy, and cryotherapy are too tedious and potentially hazardous, especially for radioisotope treatment; they have no theoretical advantage over thermal ablation and should be considered experimental at present. For centers lacking the facilities for thermal ablation, direct intralesional injection of ethanol, hot saline, hot distilled water, and even drugs is justified. The cisplatin/epinephrine gel is the first drug that has been found to be suitable for intratumoral injection and to yield a high degree of tumor necrosis. 34 The long-term treatment results of PLAT with respective to recurrence rate, progression-free survival, and overall survival are similar to those for surgical resection. Table 2 shows recent large series of surgical resection for small HCC. The overall survival rates are close to those of thermal ablation, as shown in Table 3 . However, so far no prospective randomized study has compared the efficacy of surgical A retrospective study comparing 39 patients treated with PEIT and 58 patients who underwent resection for small HCC (Ͻ3 cm and three or fewer in number) reported no difference in 1-, 3-, and 5-year recurrence-free survival and overall survival. 74 In contrast, another large retrospective study of patients with HCC less than 5 cm in diameter enrolled in the Liver Cancer Study Group of Japan found that patients who received liver resection (n ϭ 8,010) had better survival than PEIT (n ϭ 4,037) or transarterial chemoembolization (n ϭ 841). 75 However, these were not prospective randomized studies.
One explanation for surgery's superiority in the Japanese study 75 may be that the proportion of patients with associated cirrhosis was probably lower in the surgical resection group than in the nonsurgically treated group, even when the same clinical stage of the tumor was compared. Thus, metachronous multicentric carcinogenesis and development of hepatic failure would have occurred less frequently in the surgical resection group.
Most surgeons will perform concomitant resection of the whole Couinaud segment containing the tumor, based on the observation that HCC can invade the tributary of the portal branches and shed tumor emboli into the neighboring branches of the same liver segment. Thus, clearance of the tumor and potential sites of microscopic disease within the liver segment (segment-based anatomic liver resection) will be more complete and more effective for treating small HCC than nonanatomic PLAT. 76 -78 Whether the long-term treatment result of PLAT is comparable to that of surgical resection requires a prospective randomized study in patients with operable-stage small HCC. A major problem of local ablation is tumor recurrence in the liver remnant. The 3-year recurrence-free survival rate after either PEIT or thermal ablation is about 50% (see Table 3 ). Recurrence is commonly intrahepatic, 56 and adjuvant therapy after local ablation may theoretically reduce the recurrence rate. The strategy is similar to that used in surgery. A prospective randomized trial from Hong Kong reported that after "curative liver resection for HCC," patients who received a single adjuvant treatment of intraarterial Lipiodol/iodine-131 had both prolonged survival and a reduction in tumor recurrence compared with those who received no adjuvant treatment. 79 Further prospective randomized study using a similar strategy for patients after local ablation is indicated.
In conclusion, PLAT, especially with thermal ablation, produces a high degree of tumor necrosis and is effective in the local control of small HCC. Emerging data suggest superior results of RFA over PEIT. Posttreatment adjuvant therapy to reduce the rate of recurrence in the liver remnant is the next step that should be tested in an attempt to improve treatment outcome. Whether local ablation for small HCC gives similar long-term outcome compared with surgery needs to be tested in a prospective randomized study. We believe that such a study can be justified but may be difficult to carry out. 80 -84 
